ArticlePloS one2025
Investigating insulin's role in regulating local aromatase in growth plate development.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Environmental endocrine disruptors in cardio-oncology: emerging modifiers of cardiovascular vulnerability in patients with cancer.Cardio-oncology (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionObesity-associated hyperinsulinemia is hypothesized to disrupt linear growth trajectories, though the mechanisms remain unclear. This study investigates these mechanisms using a high-fat diet-induced rat model.
methodsTwelve healthy 1-week-old Sprague-Dawley rats (60-80 g) were randomized into two groups: a control group fed a standard diet and an obese group fed a high-fat diet. After 6 weeks of dietary intervention, weekly body weight and naso-anal length were recorded. At the end of the study, all rats were euthanized, and blood samples were collected for further analysis. Serum biochemical parameters, including insulin levels, were measured by ELISA. Tibiae and humeri were harvested for bone length measurement. Growth plates were isolated for histological analysis, immunohistochemistry, radioimmunoassay, PCR, and Western blotting.
resultsHigher serum insulin levels were observed in the obese group than in the control group (36.46 ± 1.69 mU/L, vs 22.96 ± 1.99 mU/L, p < 0.01). The obese group showed higher growth plate length (426.63 ± 6.28 μm, vs 331.13 ± 28.93 μm, p < 0.01), especially in proliferative and hypertrophic areas than the control group. Immunohistochemistry analysis revealed positive staining for brownish-yellow granules in these regions. Higher aromatase levels and insulin receptor (IR) expression were observed in the growth plates, primarily in the hypertrophic region. Immunohistochemical staining indicated that aromatase expression was primarily localized to the hypertrophic zone in obese rats.Moreover, the aromatase activity in the obese group was significantly higher than that in the control group (47.29 ± 0.87 U, vs 41.12 ± 1.50 U,p ＜ 0.01). The relative mRNA expression of CYP19A1 and insulin receptors (IR) in the growth plates of obese rats was significantly higher than that in the control group (0.0039 ± 0.0026-, vs 0.0001 ± 0.00025, p < 0.01 and 0.15- ± 0.07, vs 0.03 ± 0.02, p < 0.01). Western blot analysis revealed higher expression of CYP19A1 and IR in the growth plates of obese rats (1.81 ± 0.12-, vs 1.02 ± 0.04-, p < 0.01 and 2.05 ± 0.34, vs 1.04 ± 0.13-, p < 0.01).
conclusionIn this study, we found a significant increase in the expression of insulin receptors, indicating that insulin signaling regulates aromatase expression, thereby affecting epiphyseal growth plate development. However, the molecular mechanisms by which insulin receptors regulate aromatase expression remain unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.